Last reviewed · How we verify

Dexmedetomidine load — Competitive Intelligence Brief

Dexmedetomidine load (Dexmedetomidine load) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-2 adrenergic agonist. Area: Anesthesia/Sedation.

marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Anesthesia/Sedation Small molecule Live · refreshed every 30 min

Target snapshot

Dexmedetomidine load (Dexmedetomidine load) — University of Pennsylvania. Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating alpha-2 receptors in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dexmedetomidine load TARGET Dexmedetomidine load University of Pennsylvania marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor
Escitalopram+Mirtazapine Escitalopram+Mirtazapine Ministry of Health & Welfare, Korea marketed Antidepressant combination (SSRI + NaSSA) Serotonin transporter (SERT), norepinephrine transporter (NET), alpha-2 adrenergic receptors, histamine H1 receptors
Venlafaxine XR + Mirtazapine Venlafaxine XR + Mirtazapine National Institute of Mental Health (NIMH) marketed Antidepressant combination (SNRI + NaSSA) Serotonin transporter, norepinephrine transporter, alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors
mometasone furoate + Oxymetazoline mometasone furoate + Oxymetazoline Guangzhou Women and Children's Medical Center marketed Intranasal corticosteroid + nasal decongestant combination Glucocorticoid receptor (mometasone); alpha-2 adrenergic receptor (oxymetazoline)
dexmedetomidine (IN) dexmedetomidine (IN) Azienda Ospedaliera di Padova marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor
Dexmedetomidine 0.75 microgram/kg Dexmedetomidine 0.75 microgram/kg Sindh Institute of Urology and Transplantation marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor
Norepinephrine (Levophed) Norepinephrine (Levophed) University of Louisville marketed Catecholamine; sympathomimetic amine Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-2 adrenergic agonist class)

  1. USWM, LLC (dba US WorldMeds) · 2 drugs in this class
  2. China International Neuroscience Institution · 1 drug in this class
  3. Icahn School of Medicine at Mount Sinai · 1 drug in this class
  4. Eye Therapies, LLC · 1 drug in this class
  5. Galderma R&D · 1 drug in this class
  6. Guangzhou Women and Children's Medical Center · 1 drug in this class
  7. Derm Research, PLLC · 1 drug in this class
  8. Irmandade da Santa Casa de Misericordia de Sao Paulo · 1 drug in this class
  9. KK Women's and Children's Hospital · 1 drug in this class
  10. American University of Beirut Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dexmedetomidine load — Competitive Intelligence Brief. https://druglandscape.com/ci/dexmedetomidine-load. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: